thiophenes has been researched along with glucagon-like peptide 1 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, J; Banerjee, U; Bischoff, E; Cayanan, C; Dhamija, S; Fan, A; Guha, M; Herbert, MR; Heyman, RA; Kabakibi, A; Noble, SA; Pinkerton, AB; Rao, TS; Rix, P; Shiau, AK; Siegel, DL; Staszewski, L; Wang, L | 1 |
| Barrett, DG; Beavers, LS; Briere, DA; Coskun, T; Dubois, SL; Efanov, AM; Franciskovich, JB; Michael, MD; O'Farrell, LS; Syed, SK | 1 |
| Balteau, M; Beauloye, C; Behets-Wydemans, G; Bertrand, L; Castanares-Zapatero, D; Dessy, C; Gilon, P; Horman, S; Hue, L; Tajeddine, N; Timmermans, AD; Van Steenbergen, A; Vanoverschelde, JL | 1 |
| Isogawa, A; Ohki, T; Tagawa, K; Toda, N | 1 |
| Che, KK; Hu, CH; Li, DJ; Liu, L; Liu, XM; Yue, Q | 1 |
| Anno, M; Fujioka, Y; Imamura, T; Ito, Y; Izawa, S; Kato, M; Kitao, S; Matsumoto, K; Matsuzawa, K; Nakamura, R; Okura, H; Okura, T; Shoji, K; Taniguchi, SI; Ueta, E; Yamamoto, K | 1 |
1 trial(s) available for thiophenes and glucagon-like peptide 1
| Article | Year |
|---|---|
The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Humans; Insulin; Insulin Resistance; Japan; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2022 |
5 other study(ies) available for thiophenes and glucagon-like peptide 1
| Article | Year |
|---|---|
Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Hydroxyquinolines; Mice; Quinolines; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Thiophenes | 2010 |
Activation of prostaglandin E receptor 4 triggers secretion of gut hormone peptides GLP-1, GLP-2, and PYY.
Topics: Animals; Cells, Cultured; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Intestinal Mucosa; Mice; Peptide YY; Real-Time Polymerase Chain Reaction; Receptors, Prostaglandin E, EP4 Subtype; Thiophenes; Triazoles | 2013 |
AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes.
Topics: AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cells, Cultured; Glucagon-Like Peptide 1; Glucose; Hypoglycemic Agents; Male; Membrane Glycoproteins; Methylglucosides; Myocytes, Cardiac; NADPH Oxidase 2; NADPH Oxidases; Phenformin; Protein Kinase C; Protein Transport; Pyrones; Rats; Rats, Wistar; Reactive Oxygen Species; Thiophenes | 2014 |
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Pep
Topics: Alanine Transaminase; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucosides; Humans; Incretins; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.
Topics: Animals; Blood Glucose; Body Weight; Down-Regulation; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Insulin; Insulin Resistance; Intestine, Small; Liraglutide; Liver; Male; Metabolic Syndrome; Muscle, Skeletal; Pancreas; Quinolones; Rats; Signal Transduction; Thiophenes | 2021 |